Pre-made Cinrebafusp Alfa benchmark antibody (Bispecific, anti-ERBB2/HER2;TNFRSF9/CD137 therapeutic antibody, Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;ILA/4-1BB/CDw137 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Cinrebafusp Alfa benchmark antibody (Bispecific, anti-ERBB2/HER2;TNFRSF9/CD137 therapeutic antibody, Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;ILA/4-1BB/CDw137 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
cinrebafusp alfa (PRS-343), is a bispecific fusion protein that combines a 4-1BB-targeting Anticalin protein and a HER2-targeting antibody. 4-1BB is an immunoreceptor that powerfully enhances T cell proliferation, survival, and activity.
Cinrebafusp alfa bridges 4-1BB immune cells with HER2-expressing tumor cells, causing the immune cells to cluster around cancerous cells. By combining a 4-1BB-targeting Anticalin proteinwith a HER2-targeting antibody, cinrebafusp alfa focuses 4-1BB activation locally on the tumor, increasing the efficiency of the immune response and reducing systemic toxicity, compared to 4-1BB-targeting antibodies alone.
Cinrebafusp alfa has shown both clinical benefit linked to a 4-1BB mechanism of action, and robust durability, and has been observed to be safe and well-tolerated at all doses and schedules tested.
| Products Name (INN Index) | Pre-Made Cinrebafusp Alfa P Alfaiosimilar, Bispecific, Anti-ERBB2/HER2;TNFRSF9 Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;ILA/4-1BB/CDw137 therapeutic antibody |
|---|---|
| INN Name | cinrebafusp alfa |
| Target | ERBB2 |
| Format | Bispecific |
| Derivation | NA |
| Species Reactivity | NA |
| CH1 Isotype | NA |
| VD LC | NA |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | NA |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ERBB2,TNFRSF9 |
| Package |
